Tutkijat / Institutions  | Aarnio, M(arkku) (KSSHP) |
| Alafuzoff, I. (Uppsala) |
| Aro, A. (THL) |
| Aromaa, A. (THL) |
| Arvas, M(ikko) (Veripalvelu) |
| Bamford, D.H. (UH Viikki Campus) |
| Butcher, S. (UH Viikki Campus) |
| Cerullo, V. (UH Viikki Campus) |
| Ekblom-Kullberg, S(usanne) (Veripalvelu) |
| Eskola, J. (THL) |
| Finel, M(oshe) (UH Viikki Campus) |
| Gahmberg, C.G. (UH Viikki Campus) |
| Haimila, K(atri) (Veripalvelu) |
| Häkkinen, U. (THL) |
| Hanski, I(lkka) (1953-2016) (UH Viikki Campus) |
| Hari, R. (Aalto) |
| Havulinna, A(ki) S. (THL) |
| Hemminki, E. (THL) |
| Hiltunen, L(eena) (Veripalvelu) |
| Hiltunen, R(aimo) (UH Viikki Campus) |
| Holthöfer, H. (CBAS, Dublin) |
| Hovi, T. (THL) |
| Huoponen, O(uti) (Veripalvelu) |
| Huovinen, P. (THL) |
| Hyytiä, P. (THL) |
| Impola, U(lla) (Veripalvelu) |
| Jaatinen, T(aina) (Veripalvelu) |
| Jacobs, H.T. (UH Viikki Campus) |
| Jalanko, A. (THL) |
| Jalkanen, J(yrki) (KSSHP) |
| Jantunen, M. (THL) |
| Javela, K(aija) (Veripalvelu) |
| Joensuu, T(imo) (Docrates Cancer Center) |
| Jokela, J(orma) (Laurea) |
| Jokitalo, E. (UH Viikki Campus) |
| Jousilahti, P(ekka) (THL) |
| Julkunen, I. (THL) |
| Juppo, A(nne) (UH Viikki Campus) |
| Kääriäinen, H. (THL) |
| Kaartinen, T(anja) (Veripalvelu) |
| Kairemo, K(alevi) (Docrates) |
| Kallioniemi, O(lli) (SciLifeLab) |
| Karvonen, M. (THL) |
| Kayhty, H. (THL) |
| Kerkelä, E(rja) (Veripalvelu) |
| Keskimäki, I. (THL) |
| Kiianmaa, K. (THL) |
| Kinnunen, P.K. (Aalto) |
| Kirjavainen, V(esa) (Veripalvelu) |
| Klaukka, T. (Kela) |
| Korhonen, M(atti) (Veripalvelu) |
| Koskela, S(atu) (Veripalvelu) |
| Koskinen, S(eppo) (THL) |
| Kovanen, P.T. (Wihuri) |
| Kyrölä, K(ati) (KSSHP) |
| Laatikainen, T(iina) (THL) |
| Lähteenmäki, K(aarina) (Veripalvelu) |
| Laitinen, S(aara) (Veripalvelu) |
| Lappalainen, P. (UH Viikki Campus) |
| Larjo, A(ntti) (Veripalvelu) |
| Lauronen, J(ouni) (Veripalvelu) |
| Lehtinen, M(atti) (THL) |
| Leino-Arjas, P. (TTL) |
| Leinonen, M. (THL) |
| Lindros, K. (THL) |
| Linjama, T(iina) (Veripalvelu) |
| Lönnqvist, J. (THL) |
| Mäkelä, M. (THL) |
| Mäkelä, P.H. (THL) |
| Malmivaara, A(ntti) (THL) |
| Männistö, P. (UH Viikki Campus) |
| Mattila, P. (PSHP) |
| Mattila, P(irkko) (Veripalvelu/FIMM) |
| Mättö, J(aana) (Veripalvelu) |
| Natunen, S(uvi) (Veripalvelu) |
| Nissinen, A. (THL) |
| Nystedt, J(ohanna) (Veripalvelu) |
| Ovaskainen. M.L (THL). |
| Palosuo, T. (THL) |
| Palva, A(iri) (UH Viikki Campus) |
| Partanen, J(ukka) (Veripalvelu) |
| Partonen, T. (THL) |
| Patja, K. (THL) |
| Peltonen, M(arkku) (THL) |
| Peräsaari, J(uha) (Veripalvelu) |
| Pietinen, P. (THL) |
| Prattala, R. (THL) |
| Puska, P. (THL) |
| Qiao, Q(ing) (THL) |
| Reunanen, A. (THL) |
| Riihimäki, H. (TTL) |
| Ritari, J(armo) (Veripalvelu) |
| Ruotsalainen, P. (THL) |
| Ruskoaho, H(eikki) (UH Viikki Campus) |
| Ruutu, P. (THL) |
| Saarma, M. (UH Viikki Campus) |
| Saarni, S.I. (THL) |
| Saikku, P. (THL) |
| Sainio, S(usanna) (Veripalvelu) |
| Salomaa, V(eikko) (THL) |
| Shimmi, O. (UH Viikki Campus) |
| Siitonen, A. (THL) |
| Solantaus, T. (THL) |
| Thesleff, I. (UH Viikki Campus) |
| Tuomisto, J. (THL) |
| Uutela, A. (THL) |
| Vaarala, O. (THL) |
| Valsta, L. (THL) |
| Vartiainen, E(rkki) (THL) |
| Vartiainen, T. (THL) |
| Vasankari, T(ommi) (UKK) |
| Viikari-Juntura, E. (TTL) |
| Virtamo, J. (THL) |
| Virtanen, S.M. (THL) |
| Vuopio, J. (THL) |
| Wahlbeck, K. (THL) |
| Wikström, M. (UH Viikki Campus) |
Scholar Chart >>
|
»My Articles
»Latest Feeds
»Popular Feeds |
| | Human Mesenchymal Stromal Cell Secretome Promotes the Immunoregulatory Phenotype and Phagocytosis Activity in Human Macrophages | Impola, U(lla) (Veripalvelu) | 35 days | save |  |  |  |  |
| Assessment of Time-Dependent Platelet Activation Using Extracellular Vesicles, CD62P Exposure, and Soluble Glycoprotein V Content of Platelet Concentrates with Two Different Platelet Additive Solutions | Impola, U(lla) (Veripalvelu) | 35 days | save | | | | |
| Lipid mediators in platelet concentrate and extracellular vesicles: Molecular mechanisms from membrane glycerophospholipids to bioactive molecules | Impola, U(lla) (Veripalvelu) | 35 days | save | | | | |
| Graft Immune Cell Composition Associates with Clinical Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with AML | Impola, U(lla) (Veripalvelu) | 35 days | save | | | | |
| Conflicting HLA assignment by three different typing methods due to the apparent loss of heterozygosity in the MHC region | Impola, U(lla) (Veripalvelu) | 35 days | save | | | | |
| Donor Haplotype B of NK KIR Receptor Reduces the Relapse Risk in HLA-Identical Sibling Hematopoietic Stem Cell Transplantation of AML Patients | Impola, U(lla) (Veripalvelu) | 35 days | save | | | | |
| Extracellular membrane vesicles from umbilical cord blood-derived MSC protect against ischemic acute kidney injury, a feature that is lost after inflammatory conditioning | Impola, U(lla) (Veripalvelu) | 35 days | save | | | | |
| Human CMP-N-acetylneuraminic acid hydroxylase is a novel stem cell marker linked to stem cell-specific mechanisms | Impola, U(lla) (Veripalvelu) | 35 days | save | | | | |
| Glycomics of bone marrow-derived mesenchymal stem cells can be used to evaluate their cellular differentiation stage | Impola, U(lla) (Veripalvelu) | 35 days | save | | | | |
| Identification of alpha-1 acid glycoprotein as a lysophospholipid binding protein: a complementary role to albumin in the scavenging of lysophosphatidylcholine | Impola, U(lla) (Veripalvelu) | 35 days | save | | | | |
| N-glycolylneuraminic acid xenoantigen contamination of human embryonic and mesenchymal stem cells is substantially reversible | Impola, U(lla) (Veripalvelu) | 35 days | save | | | | |
| Transformation-specific matrix metalloproteinases, MMP-7 and MMP-13, are present in epithelial cells of keratoacanthomas | Impola, U(lla) (Veripalvelu) | 35 days | save | | | | |
| Expression of matrix metalloproteinase (MMP)-7 and MMP-13 and loss of MMP-19 and p16 are associated with malignant progression in chronic wounds | Impola, U(lla) (Veripalvelu) | 35 days | save | | | | |
| Matrilysin-2 (matrix metalloproteinase-26) is upregulated in keratinocytes during wound repair and early skin carcinogenesis | Impola, U(lla) (Veripalvelu) | 35 days | save | | | | |
| Matrilysin-1 (MMP-7) and MMP-19 are expressed by Paget's cells in extramammary Paget's disease | Impola, U(lla) (Veripalvelu) | 35 days | save | | | | |
| Matrix metalloproteinase-19 expression in dermal wounds and by fibroblasts in culture | Impola, U(lla) (Veripalvelu) | 35 days | save | | | | |
| Differential expression of matrilysin-1 (MMP-7), 92 kD gelatinase (MMP-9), and metalloelastase (MMP-12) in oral verrucous and squamous cell cancer | Impola, U(lla) (Veripalvelu) | 35 days | save | | | | |
| Matrix metalloproteinase-21 is expressed epithelially during development and in cancer and is up-regulated by transforming growth factor-beta1 in keratinocytes | Impola, U(lla) (Veripalvelu) | 35 days | save | | | | |
| Preliminary communication: matrix metalloproteinases in Kaposi's sarcoma | Impola, U(lla) (Veripalvelu) | 35 days | save | | | | |
| Matrix metalloproteinase-19 is expressed by keratinocytes in psoriasis | Impola, U(lla) (Veripalvelu) | 35 days | save | | | | |
| Matrix metalloproteinase-19 is expressed by proliferating epithelium but disappears with neoplastic dedifferentiation | Impola, U(lla) (Veripalvelu) | 35 days | save | | | | |
| Ectopic localization of matrix metalloproteinase-9 in chronic cutaneous wounds | Impola, U(lla) (Veripalvelu) | 35 days | save | | | | |
| Matrix metalloproteinase inhibitor BB-3103 unlike the serine proteinase inhibitor aprotinin abrogates epidermal healing of human skin wounds ex vivo | Impola, U(lla) (Veripalvelu) | 35 days | save | | | | |
| Selective binding of collagen subtypes by integrin alpha 1I, alpha 2I, and alpha 10I domains | Impola, U(lla) (Veripalvelu) | 35 days | save | | | | |
| Human Mesenchymal Stromal Cell Secretome Promotes the Immunoregulatory Phenotype and Phagocytosis Activity in Human Macrophages. | Impola, U(lla) (Veripalvelu) | 197 days | save | | | | |
| Assessment of Time-Dependent Platelet Activation Using Extracellular Vesicles, CD62P Exposure, and Soluble Glycoprotein V Content of Platelet Concentrates with Two Different Platelet Additive Solutions. | Impola, U(lla) (Veripalvelu) | 519 days | save | | | | |
| Lipid mediators in platelet concentrate and extracellular vesicles: Molecular mechanisms from membrane glycerophospholipids to bioactive molecules. | Impola, U(lla) (Veripalvelu) | 729 days | save | | | | |
| Graft Immune Cell Composition Associates with Clinical Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with AML. | Impola, U(lla) (Veripalvelu) | 1587 days | save | | | | |
| Conflicting HLA assignment by three different typing methods due to the apparent loss of heterozygosity in the MHC region. | Impola, U(lla) (Veripalvelu) | 1855 days | save | | | | |
| Donor Haplotype B of NK KIR Receptor Reduces the Relapse Risk in HLA-Identical Sibling Hematopoietic Stem Cell Transplantation of AML Patients. | Impola, U(lla) (Veripalvelu) | 2406 days | save | | | | |
| Extracellular membrane vesicles from umbilical cord blood-derived MSC protect against ischemic acute kidney injury, a feature that is lost after inflammatory conditioning. | Impola, U(lla) (Veripalvelu) | 2672 days | save | | | | |
| Human CMP-N-acetylneuraminic acid hydroxylase is a novel stem cell marker linked to stem cell-specific mechanisms. | Impola, U(lla) (Veripalvelu) | 3986 days | save | | | | |
| Glycomics of bone marrow-derived mesenchymal stem cells can be used to evaluate their cellular differentiation stage. | Impola, U(lla) (Veripalvelu) | 4310 days | save | | | | |
| N-glycolylneuraminic acid xenoantigen contamination of human embryonic and mesenchymal stem cells is substantially reversible. | Impola, U(lla) (Veripalvelu) | 5088 days | save | | | | |
| Identification of alpha-1 acid glycoprotein as a lysophospholipid binding protein: a complementary role to albumin in the scavenging of lysophosphatidylcholine. | Impola, U(lla) (Veripalvelu) | 5219 days | save | | | | |
| | 
report | | | |
|
